* Selecta Biosciences Inc SELB.OQ SELB.O is expected
to show a
rise in quarterly revenue when it reports results on May 5.
* The Watertown Massachusetts-based company is expected to
report
a 18.7% increase in revenue to $13.116 million from $11.05
million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Selecta Biosciences
Inc
is for a loss of 11 cents per share. For the same quarter last
year, the company reported a loss of 22 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Selecta
Biosciences Inc is $8, above its last closing price of $0.80.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2021 -0.08 -0.07 0.03 Beat 141.2
Sep. 30 2021 -0.03 -0.07 -0.16 Missed -115.4
Jun. 30 2021 -0.13 -0.12 0.04 Beat 134.1
Mar. 31 2021 -0.10 -0.12 -0.22 Missed -80.3
Dec. -0.09 -0.12 -0.14 Missed -21
31 2020
Sep. 30 2020 0.12 0.06 -0.09 Missed -250
Jun. 30 2020 0.12 -0.01 -0.25 Missed -3,233
.3
Mar. 31 2020 -0.27 -0.28 -0.21 Beat 24.9
This summary was machine generated May 3 at 15:19 GMT. All
figures in US dollars unless otherwise stated